Navigation Links
Clinical Trial Excellence: Shaping Markets Through Early,Communication of Clinical Trial Data

CHAPEL HILL, N.C., May 25, 2007 /PRNewswire/ -- With enormous investments and the success of a pharmaceutical product at play, pharmaceutical firms need to develop effective strategies for communicating clinical trial results early. Companies that master their communication planning and execution will gain a significant advantage in the marketplace.

According to research and consulting firm Best Practices, LLC, successful companies create communication plans long before the interim or final results for a landmark trial are available. For example, one surveyed company establishes its integrated communication strategy as early as Phase I. In addition, leading companies also develop early scenario planning for good, bad, neutral and most likely study results.

"From Breakthrough to Blockbuster: Best Practices in Communicating Clinical Trial Results" - available with a complimentary study excerpt at - examines the most effective practices for communicating clinical trial results to physicians, the managed care community, investors and consumers.

The extensive report includes over 100 best practices, metrics and narratives; a clinical communication toolkit that can help executives with the development of a communication plan or activity checklist to prepare for post- launch communication tactics. Study findings include:

    -- Communicating to Physicians: 60% of benchmarked pharmaceutical

       companies begin communicating to physicians more than six months prior

       to the drug launch. However, executives also warn that too early

       communication might trigger the opposite.

    -- Communicating to Managed Care Organizations: The information

       requirements are significantly different from the needs of physicians,

       because in addition to drug indication
s MCOs are also looking for

       complex pricing information. One benchmarked company involves pharmacy

       directors in ancillary studies that look at utilization data,

       activities necessary for government or private payers and cost-benefit-

       ratios for the drug.

    -- Communicating to Consumers: One executive identified tailoring messages

       to community and patient advocacy groups by therapeutic area as the

       most innovative public relations activity. For example, the company

       hosts separate events for consumer and advocacy leaders in the


Download the report excerpt online at to view sample best practices and performance metrics.

To drill down on the numerous metrics presented in this report more deeply contact our Solution Specialists at (919) 403-0251 or .


Best Practices, LLC, conducts work based on the simple yet profound principle that organizations can chart a course to superior economic performance by studying the best business practices, operating tactics and winning strategies of world-class companies. Best Practices, LLC has been a leader in pharmaceutical research and consulting for nearly 15 years; our clients include 43 out of the top 50 pharmaceutical companies.

CONTACT: Kimberly Hardin of Best Practices, LLC, +1-919-767-9221, or

Web site:

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Genetic Analysis Systems Enter the Clinical Mainstream
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Large Geographic Differences in EpiPen Prescriptions in the U.S., From the Journal of Allergy and Clinical Immunology
4. Clinical Data Suggest Decreased Bleeding Risk in People With Severe Hemophilia A While Maintaining Factor VIII Levels Above One Percent
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
Post Your Comments:
(Date:10/13/2015)...  Synapse Biomedical Inc. ( ) reported today ... the use of the NeuRx ® Diaphragm Pacing ... the United States and ... The PAS study group met their initial enrollment goal ... since expanded the enrollment target to 150 participants.   ...
(Date:10/13/2015)... , Oct. 13 2015 ... the "US & European markets for Meniscal ... their offering. --> ) has ... European markets for Meniscal Repair - 16 Countries ... Research and Markets ( ) has ...
(Date:10/13/2015)... Research and Markets ( ) has ... Types (Bacteria, Yeast, Mold, Others), Flavors (Herbs & Spices, ... by Region - Forecasts to 2020" report to ... --> The global market for kombucha ... terms of value, the market is projected to reach ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... In an ... utility costs were 36 percent lower per square foot than in 2009. The Williamsport ... cost of heating and cooling has decreased by eight percent. , According to ...
(Date:10/13/2015)... ... ... A child without a healthy mouth is much more likely to have an ... has joined with Global Dental Relief (GDR) to help bring dental care ... SmileCareClub will donate one clinic visit to a child in Kenya. , “When SmileCareClub ...
(Date:10/13/2015)... ... 13, 2015 , ... Scientists in Seattle and Vancouver compared the diagnostic value ... without mesothelioma. Surviving Mesothelioma has just posted an article on the new research. ... Seattle and the University of British Columbia found that certain genetic alterations were seen ...
(Date:10/13/2015)... , ... October 13, 2015 , ... World Patent ... Snow Blanket, a snow melting invention that helps people in clearing snow away from ... will continue to grow at 3.8% per year," says Scott Cooper, CEO and Creative ...
Breaking Medicine News(10 mins):